Exam Readings Rod Flashcards
(7 cards)
1
Q
Hamid et al. 2013
A
- safety and efficacy of anti pd1 antibody lambrolizumab in metastatic melanoma
- more effective than ipi
- 38% remained progression free for 7 months
- few side effects
- biopsy showed T cell infiltration
2
Q
Postow et al. 2015
A
- combo of nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) vs ipi alone
- melanoma with mt vs wt braf
- more effective than ipi alone in both wt and mt
- durable progression free responses
- associates with cd8 T cell infiltration
3
Q
Weber et al. 2024
A
- individualised neoantigen mRNA vaccine combo with pembrolizumab (anti PD1) in comparison to pembro alone
- significant reduction in recurrence and death in combination group
- T cells detectable in blood and tumour
- few side effects
4
Q
Ribas et al. 2017
A
- T-vec with pembro (antiPD1) in advanced melanoma compared to pembro alone
- 62% had tumour shrinkage
- 22% had complete response
- enhanced T cell infiltration
5
Q
Sahin et al. 2020
A
- fixvac for melanoma patients which have been desensitised to anti pd1 treatment
- increased immune activation and restored sensitivity to CPI
- majority showed partial responses
- evaluation of TCR from cd8 showed tumouricidal capacity
6
Q
Stadtmauer et al. 2020
A
- CRISPR engineered TCR targeting NY-ESO-1 and MAGE-3
- improved mismatch problems
- only 3 patients had mixed responses - one had significant regression while other 2 had partial responses
- minimal AE
- had prev been treated with CPI
7
Q
Rosenberg et al. 1988
A
- TIL therapy with IL-2 in metastatic melanoma
- 9/15 people who had no prior treatment saw regression
- IL-2 increased response
- however majority had partial responses likely due to CP
